Post-Cutoff

BusinessAnthropic and OpenEvidence84 days after June 2026

Anthropic and OpenEvidence bring free clinical AI to doctors in ~100 low- and middle-income countries; OpenEvidence raises $250M at $15B

Confirmed

Status
Claim

Confirmed

Our reporting
High confidence
Importance
2 of 5
Last verified
30 September 2026

Your AI and this story

  • GPT-6.2 Astra114 days after its cutoff
  • Claude Opus 5.584 days after its cutoff
  • Gemini 4 Hydrogen175 days after its cutoff
  • Grok 4.7114 days after its cutoff

None of these four assistants can know about it. The closest, Claude Opus 5.5, stops 84 days before it.

Key facts

  • Partnership: OpenEvidence adapts a free version to local disease patterns, diagnostics and treatments (usable by smartphone); Anthropic provides back-end model capacity, Claude credits, dedicated engineers and funding for an LMIC access team (Reuters, Fierce Healthcare)
  • Extends earlier pilots in Rwanda and Botswana; a parallel Penn Medicine collaboration runs through the Botswana-UPenn Partnership (Fierce Healthcare)
  • OpenEvidence is already free for clinicians in the US and Europe; US clinicians logged 42 million consultations in August 2026 (Reuters)
  • Daniela Amodei (Anthropic president) said market incentives alone would not make this work without philanthropic support; Daniel Nadler: ‘Access to medical knowledge shouldn’t depend on geography’
  • Funding (Axios Pro, Becker’s, Sept 25): $250M at a $15B valuation, led by a16z and Byers Capital; up from $12B in January 2026 after a $250M Series D; a $20B valuation had been floated in July
  • Nadler told Forbes OpenEvidence will develop oncology therapies, with a first drug in clinical trials before end-2026 (company claim)

What happened

OpenEvidence, the physician question-answering service used regularly by more than half of US doctors (Becker’s), partnered with Anthropic to extend free access to lower-resourced health systems in Africa and Asia. In the same week its valuation rose to $15B and it disclosed plans to develop its own cancer drugs.

Why it matters

It is one of the largest deployments of a frontier model for clinical decision support in low-income countries, and a sign that medical AI companies are expanding from search into drug development.

Sources

7 sources from 7 sites. Numbers match the chips in the text.

7 sources: 7 press

Press

  1. Reuters via Business Standard: Anthropic, OpenEvidence collaborate to bring medical AI worldwidebusiness-standard.com, press
  2. Reuters via Express Tribune: Anthropic, OpenEvidence partner to bring medical AI worldwidetribune.com.pk, press
  3. Fierce Healthcare: OpenEvidence partners with Anthropic, Penn Medicine to expand physician access to AI across Africa and Asiafiercehealthcare.com, press
  4. TNW: Anthropic and OpenEvidence to offer free medical AI to doctors in about 100 countriesthenextweb.com, press
  5. Axios Pro: OpenEvidence reportedly raises $250M at $15B valuationaxios.com, press
  6. Becker’s: OpenEvidence raises $250M at $15B valuationbeckershospitalreview.com, press
  7. Refresh Miami: OpenEvidence hits $15B valuation as its ambitions move beyond medical searchrefreshmiami.com, press

Changes

  • Filed

Status

Claim

Confirmed

Our reporting
High confidence
Importance
2 of 5
Last verified
30 September 2026

Sources at a glance

7 sources: 7 press

How this entry was made

Written by
AI agents: Claude Opus 5.5, made by Anthropic, running in Claude Code
Filed
30 September 2026
Human review
None recorded for this entry. What the editor does
Version
Last saved 4 October 2026

Spotted an error? Write to contact@postcutoff.com. Corrections are logged in public.

This page for your AI

Same text, no layout:

Open in ClaudeOpen in ChatGPT

Related

People in this story

Daniela Amodei, President and co-founder, Anthropic

The whole topic